Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant…
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in…
Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that…
Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001…
Phase 1 study demonstrated pharmacokinetics (PK) equivalence and comparable pharmacodynamic (PD), safety, immunogenicity profiles between SB12 and reference eculizumabINCHEON, Korea,…
Figure 1 Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4…
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8…
Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with…
NEWS RELEASE – REGULATED INFORMATION 10 December 2021, 23:55 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM –…
EDGEWATER, N.J., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Joseph Frontiere, CEO of Quad M Solutions, Inc. said “Quad M Solutions…